Ceritinib

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

ALK-positive Non-small Cell Lung Cancer

Conditions

ALK-positive Non-small Cell Lung Cancer

Trial Timeline

Nov 1, 2015 → May 29, 2021

NCT ID

NCT02513667

About Ceritinib

Ceritinib is a phase 2 stage product being developed by Novartis for ALK-positive Non-small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02513667. Target conditions include ALK-positive Non-small Cell Lung Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05100134	Pre-clinical	Active	—	—	Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
NCT02584933	Approved	Active	Dec 11, 2015	Jun 9, 2027	ALK Positive Malignancies
NCT02638909	Phase 2	Terminated	Dec 1, 2015	Mar 29, 2018	Colorectal Adenocarcinoma
NCT02513667	Phase 2	Terminated	Nov 1, 2015	May 29, 2021	ALK-positive Non-small Cell Lung Cancer
NCT02289144	Phase 2	Withdrawn	Jun 1, 2015	Jan 1, 2019	Metastatic Anaplastic Thyroid Cancer
NCT02343679	Phase 2	Withdrawn	May 1, 2015	Oct 1, 2022	Hematologic Malignancies
NCT02299505	Phase 1	Completed	Apr 9, 2015	Mar 6, 2020	Non-Small Cell Lung Cancer
NCT02336451	Phase 2	Completed	Apr 1, 2015	Feb 6, 2019	ALK-positive Non-small Cell Lung Cancer
NCT02186821	Phase 2	Terminated	Sep 17, 2014	Dec 13, 2017	Tumors With Aberrations in ALK or ROS1
NCT01742286	Phase 1	Completed	Aug 28, 2013	Apr 26, 2019	ALK-activated Tumors

Competing Products

9 competing products in ALK-positive Non-small Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
Crizotinib + Pembrolizumab	Merck	Phase 1	21
Ceritinib (LDK378) + Nivolumab	Novartis	Phase 1	33
Ceritinib	Novartis	Phase 2	35
ceritinib + warfarin + midazolam	Novartis	Phase 1	29
PF-02341066 + Rifampin + Itraconazole	Pfizer	Phase 1	29
Lortlatinib	Pfizer	Pre-clinical	26
Lorlatinib	Pfizer	Phase 2	31
crizotinib + alectinib + brigatinib + ceritinib + lorlatinib	Pfizer	Pre-clinical	26
PF-06463922 + Crizotinib	Pfizer	Phase 1/2	32